HomeCannabis MedicineEvaluation of decarboxylation efficiency of Δ9-tetrahydrocannabinolic acid and cannabidiolic acid by UNODC method

Evaluation of decarboxylation efficiency of Δ9-tetrahydrocannabinolic acid and cannabidiolic acid by UNODC method

June 14, 2023

Forensic Toxicol. 2023 Jan;41(1):105-113. doi: 10.1007/s11419-022-00645-7. Epub 2022 Sep 23.

ABSTRACT

PURPOSE: Decarboxylation of Δ9-tetrahydrocannabinolic acid (Δ9-THCA) to Δ9-tetrahydrocannabinol (Δ9-THC) by heating is a common method for determining total Δ9-THC. In the manual for cannabis identification and analysis, the United Nations Office on Drugs and Crime (UNODC) proposed decarboxylation conditions. Although the manual’s primary analytical target is Δ9-THC, some reports also quantified cannabidiol (CBD). The authors assessed the efficiency of decarboxylation of Δ9-THCA and cannabidiolic acid (CBDA), a carboxylated form of CBD, under four decarboxylation conditions, including the UNODC condition.

METHODS: Δ9-THCA and CBDA were heated in 2-mL glass vials at 150 °C for 12 min after the following treatment: condition A involves the addition of ethanol without capping, condition B involves non addition of solvent without capping, condition C involves non addition of solvent with capping, and condition D (UNODC condition) involves the addition of 0.5 mg/mL tribenzylamine (TBA) in ethanol without capping. The residue after heating was dissolved in methanol and then analyzed by high-performance liquid chromatography.

RESULTS: The production of Δ9-THC and CBD was low (≤ 10.1%) under conditions A and B. Under condition C, Δ9-THC production was increased (53.4%), but CBD production was hardly improved (11.7%). Under condition D, Δ9-THC and CBD production dramatically increased to 83.2 and 71.0%, respectively.

CONCLUSIONS: These findings indicated that TBA improved the production of Δ9-THC and CBD from their carboxylated forms; however, even in the presence of TBA, their production did not reach 100%. Forensic toxicologists should understand the effectiveness and limitations of decarboxylation under the UNODC condition.

PMID:36652066 | DOI:10.1007/s11419-022-00645-7

Related Posts

About The Author

Patrick Blanchard MD

Meet Dr. Blanchard Dr. Blanchard’s medical practice is an embodiment of Integrative health which brings conventional and complementary approaches together in a coordinated way. Conveniently located in sunny Florida and over the internet with ValiseMD’s secure HIPPA compliant telXmed servers. Since 1994, patients with a wide range of challenging medical problems have achieved optimum health using the best of natural medicine, judiciously combined with high-tech innovations. Breakthroughs are often achieved even after patients have consulted mainstream specialists and holistic practitioners. Dr. Blanchard is founder and CEO of ValiseMD, Inc. He is board certified in Family Medicine since 1994 and awarded Fellow of the American Academy of Family Physicians in 2001. He received the ‘Teacher of the Year’ award from the University of Kansas School of Medicine at completion of his residency in Family Medicine. He completed a fellowship at Wake Forest University in the field of vascular neurosonology. He holds a medical patent in the field of Gastroenterology. He holds an unrestricted license to practice medicine and surgery in Florida. He started his medical career as a Emergency Medical Technician, then as a Paramedic and later a Medical Doctor.